About aflo
aflo™ uses AI, sensor tech and big data to improve lung deposition, helping to control life-threatening symptoms for people with asthma and COPD.
aflo™ will teach you how to inhale your medicines correctly and aggregate your inhalation data with air quality and viral data to help you to identify asthma attack triggers.
Supported by funding from Innovate UK, CoFund, Innovation Ulster and private investors, we are building and clinically testing a hyper-personalised ‘smart inhaler’ for improved self management & quantified remote monitoring.
Meet our people
Dr Susan Kelly
CEO and Co-founder
Susan brings over fifteen years experience in Market Access/ Managed Entry for new medicines in the UK healthcare sector. Prior to forming Respiratory Analytics in 2019, to develop aflo™, she held a series of roles focused on the development of digital respiratory solutions.
Prof Liam McDaid
R&D Head and Co-founder
Liam cofounded Respiratory Analytics and leads the machine learning algorithm development, training, testing and deployment for aflo™ with our sub-contractor, Gradient Edge who have extensive experience in utilising AI within cloud computing.
Dr Jim Harkin
CTO and Co-founder
Respiratory Analytics cofounder Dr Jim Harkin will manage technical development of the aflo™ device including electronic design, manufacture and translation of the machine learning algorithm to the embedded device.
Dr Martin Kelly
Clinical Lead
Dr Martin Kelly worked in Christchurch, New Zealand before becoming a consultant respiratory physician at Altnagelvin Hospital in 2004. Martin works on a number of EU wide asthma and COPD studies and has expertise in inhaler device technology.
Dr Jack Cochran
US market entry advisor
Former Executive Director (CEO) of the Permanente Federation of Kaiser Permanente, (2007-15) during a period of major innovation in care delivery and improvement in clinical quality including the implementation of the largest civilian electronic health record. Listed in the top 50 U.S. Physician Leaders in 2009, 2010, and 2012.
Mary McKenna
Investor & Advisor
Mary McKenna is a tech entrepreneur, angel investor, an Entrepreneur in Residence at the University of Oxford, a mentor at Imperial Ventures in London and works for the EU on several Horizon Europe innovation programs. She was awarded an MBE in 2014 for services to digital technology, innovation and learning.
Robert Rosenberg
Board Chair
Robert is currently entrepreneur-in-residence at BioExel and Portershed in Galway but spent much of his career in biotech in Chicago and was instrumental in the creation of several tech companies over 20 years. Via his work in Galway, he’s mentored four cohorts of accelerator companies and startups from across Ireland.
Dr John O’Kelly
Clinical Advisor
Dr O’Kelly is a full-time partner in Aberfoyle Medical Practice. He is a member of the Advisory Group for the Cross Border Health Care Interventional Trials In Ireland Network (CHITIN) and from 2013 - 2016 was Chair of RCGP NI. He chaired the Western Area Respiratory Group and has worked with respiratory voluntary groups across Northern Ireland.
